Human adipose-derived stem cell exosome product for professional skin rejuvenation, developed by ExoCoBio Inc. (Seoul, South Korea). A lyophilised single-vial system reconstituted with a multi-active solvent containing growth factors, peptides, minerals, amino acids, and coenzymes — designed to address skin quality, firmness, hydration, and dullness in professional aesthetic settings. Backed by a published randomised controlled trial.
Professional use product. No exosome products are currently FDA-approved. Claims reflect emerging scientific literature and professional use context; individual outcomes vary and are not guaranteed.
ASCE+ SRLV is ExoCoBio's flagship human-derived skin rejuvenation product. The exosomes are isolated from human adipose tissue-derived mesenchymal stem cell (MSC) conditioned media using ExoCoBio's proprietary ExoSCRT™ tangential flow filtration process. Each vial contains 5 billion exosomes at 99% purity, with 96 miRNA types and over 200 identified proteins. The lyophilisation method is covered by Korean patent KR 10-2261434.
The solvent (5 ml) is a purpose-formulated multi-active reconstitution solution. It contains sodium hyaluronate, 5 growth factors, 6 peptides, 6 minerals, 19 amino acids, 4 coenzymes, glutathione, retinol, and vitamins. Reconstituted solution must be used within 48 hours.
The product holds ISO 22716 / GMP certification. Donor screening follows Korean MFDS (Ministry of Food and Drug Safety) protocols. Storage is 2°C–8°C with a 24-month shelf life in lyophilised form.
Regulatory note: There are currently no FDA-approved exosome products. ASCE+ SRLV is a professional aesthetic product. It is not a pharmaceutical. Evidence for human-derived exosome skin applications is developing; the published Park et al. 2023 RCT is an investigational study. For professional use only.
5 Billion MSC Exosomes per Vial — 99% Purity
Isolated from human adipose tissue-derived MSC conditioned media via ExoSCRT™ tangential flow filtration. 96 miRNA types and 200+ identified proteins. Lyophilisation method patented (KR 10-2261434). GMP-manufactured under MFDS donor screening protocols.
ExoSCRT™ Isolation Technology
ExoCoBio's proprietary tangential flow filtration process produces exosomes at verified purity levels. The same isolation platform underpins the ASCE+ HRLV Hair formulation, the hair-focused counterpart in the same product range.
Multi-Active Solvent (5 ml)
Reconstitution solution containing sodium hyaluronate, 5 growth factors, 6 peptides, 6 minerals, 19 amino acids, 4 coenzymes, glutathione, retinol, and vitamins. Designed to complement exosome activity across skin hydration, firmness, and antioxidant support.
Published RCT Evidence
Park et al. 2023 (Journal of Cosmetic Dermatology) is a 12-week randomised controlled trial with a split-face design, n=28. It is the strongest published clinical evidence for any product in this range. Results are from an independent peer-reviewed study, distinct from ExoCoBio's in-vitro and marketing data.
Storage & Format
Lyophilised 20 mg powder. Store 2°C–8°C. 24-month shelf life. Use within 48 hours of reconstitution. ISO 22716 / GMP certified.
ExoCoBio Inc., Seoul
Developer and manufacturer. ExoCoBio also produces EXOCODE Resilience-R and EXOCODE Radiance-R (topical plant-based exosome range) and ASCE+ HRLV Hair. ASCE+ SRLV is the human-derived skin rejuvenation product in the ExoCoBio professional aesthetic portfolio.
ASCE+ SRLV has the strongest published clinical evidence of any product in the Exosome Korea range. The key study:
Evidence note: The Park et al. 2023 RCT is an independent peer-reviewed study. ExoCoBio also reports in-vitro data (e.g. fibroblast activity, collagen production figures) in marketing materials. In-vitro and marketing data are not the same as RCT outcomes and should not be presented as clinical evidence on this site.
ASCE+ SRLV sits within the human-derived exosome segment of the Korean professional skin booster category. Its position alongside the published Park et al. RCT gives practitioners the most evidence-referenced option in the range. It runs as a standalone post-microneedling topical, a standalone injectable mesotherapy session, or as part of a combination energy-based device protocol.
ASCE+ SRLV uses a reconstitution system: 20 mg lyophilised exosome powder + 5 ml multi-active solvent. The exosomes and solvent actives are combined immediately before use.
Formulation note: Full INCI list and growth factor identities should be confirmed with manufacturer product documentation before clinical use. The above reflects verified publicly available specification data. Batch-to-batch specifications may vary.
Applied topically immediately after microneedling while microchannels are temporarily open. The Park et al. 2023 RCT used a split-face post-microneedling topical protocol. This is the most evidence-referenced delivery method for this product.
Administered as a standalone intradermal skin booster injection in dedicated skin quality protocols. Standard mesotherapy technique; 30G or 32G needle at intradermal depth. Reconstituted solution use within 48 hours of preparation.
Compatible with RF microneedling, Nd:YAG, and other energy-based device protocols. Exosomes, growth factors, and peptides in the solvent address post-treatment recovery and skin quality support within the same session.
Recommended protocol: 3–5 sessions at 4-week intervals for an initial course, with maintenance sessions thereafter. Reconstituted vial: use within 48 hours. Store lyophilised powder 2°C–8°C. Confirm protocol timing and technique with manufacturer guidelines and practitioner clinical judgment.
The ASCE+ range and human-derived skin rejuvenation alternatives.
Plant-based scalp rejuvenation by ExoCoBio Inc. Rosa Damascena Callus EVs (ExoSCRT™ RSCE™), 10B per vial, 598 miRNA types, 9 growth factor polypeptides. PRP-compatible. The scalp-focused product in the ASCE+ range.
View ProductHuman-derived exosome skin booster by GTM Cosmetic / CMED Co., Ltd. Dual-component lyophilised system with PDRN, tranexamic acid, and peptides for tone and brightening.
View ProductHuman dermal fibroblast multipotent cellular exosomes by BNC Global Korea Ltd. Dual-component lyophilised format for professional skin quality protocols.
View Product
